In a study involving 3,413 patients with cT2N0M0 esophageal adenocarcinoma, researchers investigated the impact of neoadjuvant chemoradiotherapy (NT) on surgical outcomes and oncological benefits for those with clinical stage IIA disease. The study found that NT did not adversely affect perioperative outcomes compared to upfront surgery. Moreover, minimally invasive esophagectomy after NT was feasible, and NT was associated with improved survival, particularly in patients with larger tumors (>5 cm). This study suggests that NT is a valuable option for selected cT2N0M0 esophageal adenocarcinoma patients.
Journal Article by Rodriguez-Quintero JH, Kamel MK (…) Stiles BM et 4 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.